Alpha Cognition Inc. Common Stock (ACOG) News
Track canonical SquawkNews coverage tagged to ACOG, Alpha Cognition Inc. Common Stock. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 5 indexed stories across 3 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Alpha Cognition reports Q2 2026 revenue, trims opex guidance
Alpha Cognition reported about $6 million in net product revenue for Q2 2026, said it reduced full-year 2026 operating expense guidance to $50 million-$54 million, and cited 94% GAAP gross product margin.
EARNINGS | Aug 13, 2026, 09:20 PM UTC
L
Alpha Cognition (ACOG) Reports Q2 2026 Results, Operational Update
Alpha Cognition Inc. (ACOG) reports its second quarter 2026 financial results and provides an operational update, with no additional figures or details supplied in the feed.
EARNINGS | Aug 13, 2026, 08:11 PM UTC
H
ACOG Receives European Patent
ACOG gets patent for Alzheimer's treatment
EQUITY | Jul 29, 2026, 12:33 PM UTC
H
Alpha Cognition Receives European Patent
Alpha Cognition gets patent for Alzheimer's treatment
EQUITY | Jul 29, 2026, 12:31 PM UTC
L
Alpha Cognition initiated with an Outperform at Raymond James
Raymond James analyst Ryan Deschner initiated coverage of Alpha Cognition with an Outperform rating and $20 price target. Alpha Cognition markets Zunveyl, a prodrug of FDA-approved galantamine, which is indicated for the
REGULATION | Jul 10, 2026, 10:12 AM UTC